The Prevalence of Osteoporosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
CLINICIANS HAVE ALWAYS BEEN MOVED by the suffering of their patients to develop better approaches to disease management. This is certainly true in the case of osteoporosis where, for example, it may prove difficult to ameliorate the chronic symptoms of a woman suffering from multiple vertebral compression fractures. With a view to preventing such fractures, there has been an explosion of diagnostic and therapeutic technologies in recent years, although many important questions (and exciting opportunities) remain to be explored. However, funding for the necessary research, and for the clinical application of these advances, depends upon societal recognition of the importance of the problem. Authoritative opinions on the subject from leaders in the field are not sufficient to assure this. Instead, data are needed concerning the frequency, cost, and societal impact of osteoporosis and its attendant fractures. With this in mind, a working group of the World Health Organization (WHO) developed the now-familiar operational definition of osteoporosis, i.e., a bone mineral density (BMD) level more than 2.5 standard deviations (SD) below the young normal mean.1 Some have criticized this approach because it does not lend itself to treatment decisions for individual patients: clinicians may feel that prophylaxis is indicated for patients who do not yet have osteoporosis or even low bone mass, while others may be disinclined to aggressively treat some elderly patients even though they have severe osteoporosis. The need has been for treatment thresholds that, while based on bone density measurements, recognize that other factors such as life expectancy and various risk factors also contribute to fracture prediction. This gap is being filled in part by analyses from the National Osteoporosis Foundation that define subsets of patients in whom various treatments are likely to be cost effective.2 Because specific treatments have different long-term risks and benefits, however, the treatment threshold is unique for each one. This makes perfect sense clinically but it is not possible on this basis to define the prevalence of osteoporosis, which would then rise or fall depending upon the therapy that was envisioned. Thus, to serve the social need, if not to treat patients, it is important to have a more or less consistent definition of osteoporosis in order to document the frequency of the condition for policymakers. Even if one accepts the WHO definition of osteoporosis, there have been serious limitations with respect to available data. Most important is uncertainty about the prevalence of osteoporosis among men and nonwhite women. Recent estimates indicate that 18% of the cost of osteoporotic fractures in the United States in 1995, or $2.5 billion, was spent treating white men and another 7%, or $900 million, was spent on nonwhite women and men.3 Even among white women, who accounted for 75% of total expenditures, or $10.3 billion, only rough estimates of osteoporosis prevalence have been available, as projected from a small population-based sample of Rochester, Minnesota women.4 The availability of high quality data from a probability sample of the United States population has changed that. Based on data from the first phase of the third National Health and Nutrition Examination Survey (NHANES III), Looker and colleagues determined that the prevalence of osteoporosis of the total hip was 21% among white women compared with 16% among Hispanic women and only 10% among African-American women.5 In this issue of the Journal, these analyses have been enlarged and extended to men.6 Using additional data from the second phase of NHANES III, prevalence rates for osteopenia and osteoporosis of the proximal femur were recalculated for the three groups of American women. For the first time, prevalence rates were also estimated for men. Because it is not clear what standard should be used, two approaches were taken. Based on a definition of osteoporosis using the same absolute bone density cutoff level for men as for women (e.g., 0.56 g/cm2 for femoral neck BMD), the prevalence rates for white, Hispanic, and African-American men age 50 years and over were 4, 2, and 3%, respectively. The lower prevalence in men is consistent with their lower risk of hip fracture7 and reflects the fact that total hip bone density is 12–13% greater in men.8 Because of their larger skeletons, however, areal bone density may be overestimated in men.9 Consequently, osteoporosis prevalence rates were also calculated on the basis of bone density levels more than 2.5 SD below the mean for young men (e.g., a cut-off level of 0.59 g/cm2 for femoral neck BMD). The higher mean value caused the prevalence rates for white, Hispanic, and African-American men to increase to 7, 3, and 5%, respectively. The modest size of this change reflects the fact that bone loss in older men is not as rapid as in older women8 so that the osteoporotic patients are derived disproportio
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Self-citationMarshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Matkovic, V, Jelic, T., Wardlaw, G. M., Ilich, J. Z., Goel, P. K., Wright, J. K., Andon, M. B., Smith, K. T., & Heaney, R. P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117034 · Cited by 806 · cited 1×
“However, cross-sectional data show no loss of bone from the distal forearm until the time of menopause.((15,16)) Findings from the lumbar spine are less clear but seem to indicate continued bone gain until the 30s.”
Background
Cited by
A reference standard for the description of osteoporosis
Kanis, J. A., McCloskey, E. V., Johansson, H., Oden, A., Melton, L. J., & Khaltaev, N. (2008) · Bone · doi:10.1016/j.bone.2007.11.001 · Cited by 1,234
Self-citationBone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
Siris, E. S., Chen, Y.-T., Abbott, T. A., Barrett-Connor, E., Miller, P. D., Wehren, L. E., & Berger, M. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1108 · Cited by 1,093
An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry
Kanis, J. A., & Glüer, C.-C. (2000) · Osteoporosis International · doi:10.1007/s001980050281 · Cited by 952
Clinical Use of Bone Densitometry: Scientific Review
Cummings, S. R., Bates, D., & Black, D. M. (2002) · JAMA · doi:10.1001/jama.288.15.1889 · Cited by 817
Bone Density and Fracture Risk in Men
Dr. Melton, L. J., Atkinson, E. J., O'Connor, M. K., O'Fallon, W. M., & Riggs, B. L. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.12.1915 · Cited by 684
Metadata
- Authors
- Melton, L. J.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-11-01
- Volume
- 12
- Issue
- 11
- Pages
- 1769-1771
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2046927217
- Cited by
- 103
- References
- 3
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Prevalence of Osteoporosis. https://app.cochat.ai/papers/10.1359/jbmr.1997.12.11.1769
- The paper
- Melton, L. J. (1997). The Prevalence of Osteoporosis. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.1997.12.11.1769
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.